Zydus Lifesciences Shares Up 2.80%; Q4 Revenue Jumps 16% 

Mumbai, May 19: Shares of Zydus Lifesciences Ltd (ZYDUSLIFE) ended Tuesday’s session firmly in positive territory, closing at ₹1,018.90, up ₹27.80 or 2.80% from its previous close of ₹991.10, as strong quarterly results and a significant share buyback announcement drove sustained buying interest through the day.

The stock opened at ₹995.00 — a modest gap-up from the previous close — and traded in a relatively tight range between ₹995.00 and ₹1,010 for the bulk of the morning and midday session, reflecting measured accumulation rather than an aggressive opening surge.

The real action arrived in the afternoon, with the stock surging sharply after 14:00 hours to hit an intraday high of ₹1,048.00, before paring some of those gains to settle at the closing price of ₹1,018.90. The VWAP of ₹1,028.11 suggested that the late-session spike drew some profit-booking, pulling the close slightly below the day’s volume-weighted average. The order book at close showed 100% on the buy side with zero sell orders in the visible depth, pointing to a complete absence of seller pressure at closing levels — an unusually bullish order book configuration.

Weekly Trend

The weekly chart reinforced the strength of the ongoing recovery. ZYDUSLIFE had started the week of May 12 at approximately ₹928, climbed steadily through May 13 and touched ₹993.65 by May 14, before consolidating just above ₹1,000 on May 15 at around ₹1,008 — its weekly high before Tuesday’s session. The stock then pulled back slightly to close Monday around ₹991, making Tuesday’s close of ₹1,018.90 a fresh weekly high and a gain of approximately ₹91 or nearly 9.8% from the May 12 opening, reflecting a powerful week-long recovery underpinned by results-driven momentum.

Q4 FY26 Consolidated Financial Highlights

Zydus Lifesciences delivered a sharply improved quarterly performance for Q4 FY26. Revenue from operations rose 16.2% year-on-year to Rs. 75,870 million from Rs. 65,279 million in Q4 FY25. EBITDA surged 20.2% year-on-year to Rs. 25,544 million from Rs. 21,255 million, with the EBITDA margin expanding 110 basis points to 33.7% from 32.6% a year ago.

Net profit for Q4 FY26 came in at Rs. 15,929 million, up 14.6% year-on-year from Rs. 13,905 million in Q4 FY25, adjusted for exceptional items including a one-time spend of Rs. 3,975 million towards the Mirabegron litigation settlement during the quarter.

FY26 Full-Year Consolidated Financial Highlights

For the full year ended March 31, 2026, Zydus Lifesciences delivered broad-based growth across all key metrics. Revenue from operations grew 16.8% year-on-year to Rs. 2,71,484 million from Rs. 2,32,415 million in FY25. EBITDA rose 20.1% to Rs. 84,751 million from Rs. 70,585 million, with the full-year EBITDA margin expanding 80 basis points to 31.2% from 30.4%. Net profit for FY26 grew 15.0% year-on-year to Rs. 54,564 million from Rs. 47,451 million, while PBT rose 14.3% to Rs. 71,377 million from Rs. 62,463 million, reflecting disciplined cost management alongside strong topline momentum.

Dividend and Buyback

The Board recommended a dividend of 100% for FY2025-26. Additionally, the Board approved a buyback of equity shares for an aggregate amount of up to Rs. 11,000 million at a price of Rs. 1,150 per share, representing a 16% premium to the closing price of May 18, 2026, signalling strong management confidence in the company’s financial position and future prospects.

Source: https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited